The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

<i>Coot</i> : model-building tools for molecular graphics

Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,671 · see citing works

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,949 · see citing works

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · see citing works

A gene complex controlling segmentation in Drosophila

Lewis, E. B. (1978) · Nature · doi:10.1038/276565a0 · Cited by 3,813 · see citing works

Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions

Krissinel, E., & Henrick, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904026460 · Cited by 3,785 · see citing works

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · see citing works

The Polycomb complex PRC2 and its mark in life

Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · see citing works

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420 · see citing works

Data processing and analysis with the autoPROC toolbox

Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O. S., Paciorek, W. A., Womack, T. O., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,084 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

Role of histone H2A ubiquitination in Polycomb silencing

Wang, H., Wang, L., Erdjument‐Bromage, H., Vidal, M., Tempst, P., Jones, R. S., & Zhang, Y. (2004) · Nature · doi:10.1038/nature02985 · Cited by 1,770 · see citing works

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,670 · see citing works

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · see citing works

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes &amp; Development · doi:10.1101/gad.1035902 · Cited by 1,596 · see citing works

Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · see citing works

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works

Mechanisms of Polycomb gene silencing: knowns and unknowns

Simon, J. A., & Kingston, R. E. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2763 · Cited by 1,320 · see citing works

Role of the polycomb protein EED in the propagation of repressive histone marks

Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,203 · see citing works

EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency

Shen, X., Liu, Y., Hsu, Y.-J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.-C., & Orkin, S. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.016 · Cited by 1,021 · see citing works

Analysis of the coding genome of diffuse large B-cell lymphoma

Pasqualucci, L., Trifonov, V. A., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V. A., Grunn, A., Messina, M., Elliott, O., et al. (2011) · Nature Genetics · doi:10.1038/ng.892 · Cited by 971 · see citing works

The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development

O’Carroll, D., Erhardt, S., Pagani, M., Barton, S. C., Surani, M. A., & Jenuwein, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4330-4336.2001 · Cited by 908 · see citing works

High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery

Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J. C., Graf, E., Carver, T., Asel, E. D., Springer, B. A., Lane, P. D., et al. (2001) · SLAS DISCOVERY · doi:10.1177/108705710100600609 · Cited by 899 · see citing works

Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms

Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C. L. F., Dynlacht, B. D., & Reinberg, D. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.11.004 · Cited by 889 · see citing works

Transcriptional regulation by Polycomb group proteins

Di Croce, L., & Helin, K. (2013) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2669 · Cited by 864 · see citing works

Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene Silencing

Cao, R., Tsukada, Y.-I., & Zhang, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.12.002 · Cited by 847 · see citing works

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794 · see citing works

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · see citing works

A model for transmission of the H3K27me3 epigenetic mark

Hansen, K. H., Bracken, A. P., Pasini, D., Dietrich, N., Gehani, S. S., Monrad, A., Rappsilber, J., Lerdrup, M., & Helin, K. (2008) · Nature Cell Biology · doi:10.1038/ncb1787 · Cited by 720 · see citing works

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes &amp; Development · doi:10.1101/gad.217778.113 · Cited by 707 · see citing works

The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation

Pasini, D., Bracken, A. P., Hansen, J. B., Capillo, M., & Helin, K. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01432-06 · Cited by 696 · see citing works

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 691 · see citing works

Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery

Lo, M.-C., AULABAUGH, A. E., Jin, G., Cowling, R. A., Bard, J., Malamas, M. S., & Ellestad, G. A. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.04.031 · Cited by 688 · see citing works

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 493 · see citing works

An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1

Konze, K. D., Ma, A., Li, F., Baršytė-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 450 · see citing works

Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2

Justin, N., Zhang, Y., Tarricone, C., Martin, S. R., Chen, S., Underwood, E., Marco, V. D., Haire, L. F., Walker, P. A., Reinberg, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11316 · Cited by 403 · see citing works

Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2

Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402 · see citing works

The Core of the Polycomb Repressive Complex Is Compositionally and Functionally Conserved in Flies and Humans

Levine, S. S., Weiss, A., Erdjument‐Bromage, H., Shao, Z., Tempst, P., & Kingston, R. E. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6070-6078.2002 · Cited by 388 · see citing works

Recognition and Specificity Determinants of the Human Cbx Chromodomains

Kaustov, L., Ouyang, H., Amaya, M. F., Lemak, A. S., Nady, N., Duan, S., Wasney, G. A., Li, Z., Vedadi, M., Schapira, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191411 · Cited by 306 · see citing works

The eed mutation disrupts anterior mesoderm production in mice

Faust, C. J., Schumacher, A., Holdener, B. C., & Magnuson, T. (1995) · Development · doi:10.1242/dev.121.2.273 · Cited by 295 · see citing works

Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer

Sadiković, B., Al-Romaih, K. I., Squire, J. A., & Zieleńska, M. (2008) · Current Genomics · doi:10.2174/138920208785699580 · Cited by 292 · see citing works

A new world of Polycombs: unexpected partnerships and emerging functions

Schwartz, Y. B., & Pirrotta, V. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3603 · Cited by 277 · see citing works

Molecular recognition of histone H3 by the WD40 protein WDR5

Couture, J., Collazo, E., & Trievel, R. C. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1116 · Cited by 256 · see citing works

Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)

Xu, C., Bian, C., Yang, W., Galka, M., Ouyang, H., Chen, C., Qiu, W., Liu, H., Jones, A. E., MacKenzie, F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008937107 · Cited by 221 · see citing works

( R )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells

Baršytė-Lovejoy, D., Li, F., Oudhoff, M. J., Tatlock, J. H., Dong, A., Zeng, H., Wu, H., Freeman, S. A., Schapira, M., Senisterra, G. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407358111 · Cited by 187 · see citing works

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M. J., & Martinez-Climent, J. A. (2014) · Blood · doi:10.1182/blood-2014-03-560284 · Cited by 187 · see citing works

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Brooun, A., Gajiwala, K. S., Deng, Y., Liu, W., Bolaños, B., Bingham, P., He, Y.-A., Diehl, W. C., Grable, N., Kung, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11384 · Cited by 164 · see citing works

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty, S., Nasveschuk, C. G., Gagnon, A., Chan, E. Y., Sandy, P., Busby, J., Balasubramanian, S., Campbell, R., Zhao, F., Bergeron, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.013 · Cited by 154 · see citing works

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors

Gibaja, V, Shen, F., Harari, J., Korn, J., Ruddy, D., Saenz-Vash, V, Zhai, H., Rejtar, T., Paris, C. G., Yu, Z., et al. (2016) · Oncogene · doi:10.1038/onc.2015.114 · Cited by 149 · see citing works

Thermal Denaturation Assays in Chemical Biology

Senisterra, G. A., Chau, I., & Vedadi, M. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.0390 · Cited by 148 · see citing works

EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas

Ryan, R. J. H., Nitta, M., Borger, D. R., Zukerberg, L. R., Ferry, J. A., Harris, N. L., Iafrate, A. J., Bernstein, B., Sohani, A. R., & Le, L. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028585 · Cited by 122 · see citing works

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

Pappano, W. N., Guo, J. Q., He, Y., Ferguson, D. C., Jagadeeswaran, S., Osterling, D. J., Gao, W., Spence, J. K., Pliushchev, M. A., Sweis, R. F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131716 · Cited by 100 · see citing works

Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors

Baker, T. E., Nerle, S., Pritchard, J. R., Zhao, B., Rivera, V. M., Garner, A. P., & Gonzalvez, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5066 · Cited by 78 · see citing works

EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes

Hernando, H., Gelato, K. A., Lesche, R., Beckmann, G., Koehr, S., Otto, S., Steigemann, P., & Stresemann, C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0486 · Cited by 62 · see citing works

EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms

Ueda, T., Sanada, M., Matsui, H., Yamasaki, N., Honda, Z.-I., Shih, L.-Y., Mori, H., Inaba, T., Ogawa, S., & Honda, H. (2012) · Leukemia · doi:10.1038/leu.2012.146 · Cited by 54 · see citing works

The structure–activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface

Camerino, M. A., Zhong, N., Dong, A., Dickson, B. M., James, L. I., Baughman, B. M., Norris, J. L., Kireev, D., Janzen, W. P., Arrowsmith, C. H., et al. (2013) · MedChemComm · doi:10.1039/c3md00197k · Cited by 24 · see citing works

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works

Targeted protein degradation: expanding the toolbox

Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 402 · see citing works

The roles of Polycomb repressive complexes in mammalian development and cancer

Piunti, A., & Shilatifard, A. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00341-1 · Cited by 382 · see citing works

WD40 repeat domain proteins: a novel target class?

Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335 · see citing works

Inhibitors of Protein Methyltransferases and Demethylases

Kanıskan, H. Ü., Martini, M. L., & Jin, J. J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 320 · see citing works

Chemical and Biochemical Perspectives of Protein Lysine Methylation

Luo, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00008 · Cited by 288 · see citing works

Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area

Xu, R., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 262 · see citing works

PRC2 is high maintenancePreprint

Yu, J.-R., Lee, C., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 248 · see citing works

Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 243 · see citing works

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202 · see citing works

Enhancer of zeste homolog 2 (EZH2) inhibitors

Gulati, N., Béguelin, W., & Giulino-Roth, L. G. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 196 · see citing works

Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancerPreprint

Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 192 · see citing works

Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader

Potjewyd, F., Turner, A. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 179 · see citing works

RNA-modifying proteins as anticancer drug targets

Boriack‐Sjodin, P. A., Ribich, S. A., & Copeland, R. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.71 · Cited by 154 · see citing works

The roles of EZH2 in cancer and its inhibitors

Liu, Y., & Yang, Q. (2023) · Medical Oncology · doi:10.1007/s12032-023-02025-6 · Cited by 147 · see citing works

H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2

Jain, S. U., Rashoff, A. Q., Krabbenhoft, S. D., Hoelper, D., Do, T. J., Gibson, T. J., Lundgren, S. M., Bondra, E. R., Deshmukh, S., Harutyunyan, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.028 · Cited by 142 · see citing works

Engaging chromatin: PRC2 structure meets function

Chammas, P., Mocavini, I., & Croce, L. D. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0615-2 · Cited by 138 · see citing works

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate ( R )-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2 H )-one (PF-06821497)

Kung, P., Bingham, P., Brooun, A., Collins, M. R., Deng, Y., Dinh, D. M., Fan, C., Gajiwala, K. S., Grantner, R., Gukasyan, H. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01375 · Cited by 138 · see citing works

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling

Scheer, S., Ackloo, S. Z., Medina, T. D. S., Schapira, M., Li, F., Ward, J. A., Lewis, A. M., Northrop, J. P., Richardson, P. L., Kanıskan, H. Ü., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07905-4 · Cited by 136 · see citing works

Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin

Lee, C., Yu, J.-R., Kumar, S., Jin, Y., LeRoy, G., Bhanu, N. V., Kaneko, S., Garcia, B. A., Hamilton, A. D., & Reinberg, D. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.020 · Cited by 135 · see citing works

Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds

Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 119 · see citing works

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer

Jones, B. A., Varambally, S., & Arend, R. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0437 · Cited by 115 · see citing works

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 108 · see citing works

RNA exploits an exposed regulatory site to inhibit the enzymatic activity of PRC2

Zhang, Q., Mckenzie, N., Warneford-Thomson, R., Gail, E. H., Flanigan, S. F., Owen, B. M., Lauman, R., Levina, V., Garcia, B. A., Schittenhelm, R. B., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0197-y · Cited by 104 · see citing works

Building C(sp3)-rich complexity by combining cycloaddition and C–C cross-coupling reactions

Chen, T., Barton, L. M., Lin, Y., Tsien, J., Kossler, D., Bastida, I., Asai, S., Bi, C., Chen, J. S., Shan, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0391-9 · Cited by 88 · see citing works

A cis-acting mechanism mediates transcriptional memory at Polycomb target genes in mammals

Holoch, D., Wassef, M. A., Lövkvist, C., Zielinski, D., Aflaki, S., Lombard, B., Héry, T., Loew, D., Howard, M., & Margueron, R. (2021) · Nature Genetics · doi:10.1038/s41588-021-00964-2 · Cited by 79 · see citing works

Integrated Platform for Expedited Synthesis–Purification–Testing of Small Molecule Libraries

Baranczak, A., Tu, N. P., Marjanovic, J., Searle, P. A., Vasudevan, A., & Djurić, S. W. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00054 · Cited by 83 · see citing works

Live-cell imaging reveals the dynamics of PRC2 and recruitment to chromatin by SUZ12-associated subunitsPreprint

Youmans, D. T., Schmidt, J. C., & Cech, T. R. (2018) · Genes & Development · doi:10.1101/gad.311936.118 · Cited by 81 · see citing works

EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing

Kang, N., Eccleston, M., Clermont, P., Latarani, M., Male, D. K., Wang, Y. Z., & Crea, F. (2020) · Epigenomics · doi:10.2217/epi-2020-0186 · Cited by 76 · see citing works

Targeting Histone Methylation in Cancer

McCabe, M. T., Mohammad, H. P., Barbash, O., & Kruger, R. G. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000283 · Cited by 73 · see citing works

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer

Wassef, M. A., Luscan, A., Aflaki, S., Zielinski, D., Jansen, P. W. T. C., Baymaz, H. I., Battistella, A., Kersouani, C., Servant, N., Wallace, M. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814634116 · Cited by 63 · see citing works

Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF

Radko-Juettner, S., Yue, H., Myers, J., Carter, R. D., Robertson, A. N., Mittal, P., Zhu, Z., Hansen, B. S., Donovan, K. A., Hunkeler, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07250-1 · Cited by 65 · see citing works

Polycomb complexes in normal and malignant hematopoiesis

Carlo, V. D., Mocavini, I., & Croce, L. D. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201808028 · Cited by 61 · see citing works

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies

Huang, Y. R., Sendzik, M., Zhang, J., Gao, Z., Sun, Y., Wang, L., Gu, J., Zhao, K., Yu, Z., Zhang, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02148 · Cited by 62 · see citing works

Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer

Martin, M. C., Zeng, G., Yu, J., & Schiltz, G. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01344 · Cited by 62 · see citing works

Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7

Lamb, K. N., Bsteh, D., Dishman, S. N., Moussa, H. F., Fan, H., Stuckey, J. I., Norris, J. L., Cholensky, S. H., Li, D., Wang, J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.013 · Cited by 60 · see citing works

Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective

Webb, T., Craigon, C., & Ciulli, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128653 · Cited by 59 · see citing works

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Vleet, T. R. V., Liguori, M. J., Lynch, J. J., Rao, M. S., & Warder, S. E. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218799713 · Cited by 60 · see citing works

Targeting non-bromodomain chromatin readers

Arrowsmith, C. H., & Schapira, M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0290-2 · Cited by 58 · see citing works

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy

Kazansky, Y., Cameron, D., Mueller, H. S., Demarest, P., Zaffaroni, N., Arrighetti, N., Zuco, V., Kuwahara, Y., Somwar, R., Ladanyi, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0110 · Cited by 59 · see citing works

PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components

Bashore, F. M., Foley, C. A., Ong, H. W., Rectenwald, J. M., Hanley, R. P., Norris-Drouin, J. L., Cholensky, S. H., Mills, C. A., Pearce, K. H., Herring, L. E., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00804 · Cited by 56 · see citing works

Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor

de Freitas, R. F., Ivanochko, D., & Schapira, M. (2019) · Molecules · doi:10.3390/molecules24244492 · Cited by 54 · see citing works

An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response

Dong, H., Liu, S., Zhang, X., Chen, S., Kang, L., Chen, Y., Ma, S., Fu, X., Liu, Y., Zhang, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0428 · Cited by 54 · see citing works

Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders

Tomassi, S., Romanelli, A., Zwergel, C., Valente, S., & Mai, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00226 · Cited by 56 · see citing works

The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity

Di, Y., Jing, X., Hu, K., Wen, X., Ye, L., Zhang, X., Qin, J., Ye, J., Lin, R., Wang, Z., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100909 · Cited by 53 · see citing works

Single-cell epigenomic reconstruction of developmental trajectories from pluripotency in human neural organoid systems

Zenk, F. L., Fleck, J. S., Jansen, S. M. J., Kashanian, B., Eisinger, B., Santel, M., Dupré, J.-S., Camp, J. G., & Treutlein, B. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01652-0 · Cited by 53 · see citing works

Conformational dynamics of the TTD–PHD histone reader module of the UHRF1 epigenetic regulator reveals multiple histone-binding states, allosteric regulation, and druggability

Houliston, R. S., Lemak, A. S., Iqbal, A., Ivanochko, D., Duan, S., Kaustov, L., Ong, M. S., Fan, L., Senisterra, G. A., Brown, P. J., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.799700 · Cited by 51 · see citing works

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain

Senisterra, G. A., Zhu, H. Y. H., Luo, X., Zhang, H., Xun, G., Lu, C., Xiao, W., Hajian, T., Loppnau, P., Chau, I., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218766278 · Cited by 51 · see citing works

Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery

Copeland, R. A. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0080 · Cited by 51 · see citing works

Epigenetic small molecule modulators of histone and DNA methylation

Hauser, A., Robaa, D., & Jung, M. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.03.003 · Cited by 50 · see citing works

Drugging histone methyltransferases in cancer

Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 49 · see citing works

EZH2 inhibitors: a patent review (2014-2016)

Stazi, G., Zwergel, C., Mai, A., & Valente, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1316976 · Cited by 49 · see citing works

Drug Discovery and Chemical Biology of Cancer Epigenetics

Ribich, S. A., Harvey, D. M., & Copeland, R. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.020 · Cited by 49 · see citing works

Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation

Čermáková, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 49 · see citing works

Lysine methyltransferase inhibitors: where we are now

Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 48 · see citing works

Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation

Zaware, N., & Zhou, M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.012 · Cited by 47 · see citing works

Targeting epigenetic machinery: Emerging novel allosteric inhibitors

Ye, F., Huang, J. L., Wang, H., Luo, C., & Zhao, K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107406 · Cited by 45 · see citing works

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)

Dockerill, M., Gregson, C. L., & O’Donovan, D. H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841167 · Cited by 46 · see citing works

Disease Association and Druggability of WD40 Repeat Proteins

Song, R., Wang, Z.-D., & Schapira, M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00451 · Cited by 45 · see citing works

Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective

Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45 · see citing works

Recent progress in developing selective inhibitors of protein methyltransferases

Kanıskan, H. Ü., & Jin, J. J. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.013 · Cited by 44 · see citing works

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis

Schmidt, O., Nehls, N., Prexler, C., von Heyking, K., Groll, T., Pardon, K., García, H. D., Hensel, T., Gürgen, D., Henssen, A. G., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02125-z · Cited by 44 · see citing works

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction

Du, D., Xu, D., Zhu, L., Stazi, G., Zwergel, C., Liu, Y., Luo, Z., Li, Y., Zhang, Y., Zhu, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02261 · Cited by 44 · see citing works

Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer

Berdasco, M., & Esteller, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15604 · Cited by 43 · see citing works

PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function

Liu, X., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894585 · Cited by 44 · see citing works

PALI1 facilitates DNA and nucleosome binding by PRC2 and triggers an allosteric activation of catalysis

Zhang, Q., Agius, S. C., Flanigan, S. F., Uckelmann, M., Levina, V., Owen, B. M., & Davidovich, C. (2021) · Nature Communications · doi:10.1038/s41467-021-24866-3 · Cited by 42 · see citing works

Exploiting Epigenetic Alterations in Prostate Cancer

Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 41 · see citing works

A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine

Catalano, R., Rocca, R., Juli, G., Costa, G., Maruca, A., Artese, A., Caracciolo, D., Tagliaferri, P., Alcaro, S., Tassone, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111715 · Cited by 38 · see citing works

The control of polycomb repressive complexes by long noncoding RNAs

Trotman, J. B., Braceros, K. C. A., Cherney, R. E., Murvin, M. M., & Calabrese, J. M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1657 · Cited by 37 · see citing works

EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer

Chen, Y., Zhu, H., Luo, Y., Tong, S., & Liu, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116624 · Cited by 35 · see citing works

Targeting protein methylation: from chemical tools to precision medicines

Dilworth, D., & Baršytė-Lovejoy, D. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03147-9 · Cited by 35 · see citing works

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development

Rej, R. K., Wang, C., Lü, J., Wang, M., Petrunak, E. M., Zawacki, K. P., McEachern, D., Fernández‐Salas, E., Yang, C., Wang, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00479 · Cited by 35 · see citing works

Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer

Li, X., Gera, L., Zhang, S., Chen, Y., Lou, L., Wilson, L. M., Xie, Z., Sautto, G. A., Liu, D., Danaher, A., et al. (2021) · Theranostics · doi:10.7150/thno.49235 · Cited by 35 · see citing works

Structure-based view of the druggable genome

Wang, J., Yazdani, S., Han, A., & Schapira, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.006 · Cited by 34 · see citing works

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression

Rej, R. K., Wang, C., Lü, J., Wang, M., Petrunak, E. M., Zawacki, K. P., McEachern, D., Yang, C., Wang, L., Li, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01059 · Cited by 34 · see citing works

Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics

Wang, M. Y., Liow, P., Guzman, M. I. T., & Qi, J. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00062 · Cited by 34 · see citing works

Methyllysine binding domains: Structural insight and small molecule probe development

Teske, K. A., & Hadden, M. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.047 · Cited by 32 · see citing works

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Bagal, S. K., Gregson, C. L., O’Donovan, D. H., Pike, K. G., Bloecher, A., Barton, P., Borodovsky, A., Code, E. L., Fillery, S. M., Hsu, J. H.-R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01161 · Cited by 32 · see citing works

Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer

Petros, A. M., Korepanova, A., Jakob, C. G., Qiu, W., Panchal, S. C., Wang, J., Dietrich, J. D., Brewer, J. T., Pohlki, F., Kling, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00178 · Cited by 32 · see citing works

Polycomb-group proteins in the initiation and progression of cancer

Zhao, X., & Wu, X. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.013 · Cited by 31 · see citing works

Expanding the ligand spaces for E3 ligases for the design of protein degraders

Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 29 · see citing works

SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding

Curtin, M. L., Pliushchev, M. A., Li, H., Torrent, M., Dietrich, J. D., Jakob, C. G., Zhu, H., Zhao, H., Wang, Y., Ji, Z., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.02.030 · Cited by 30 · see citing works

Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine

Engelberg, I. A., Foley, C. A., James, L. I., & Frye, S. V. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.002 · Cited by 27 · see citing works

Chemical biology and pharmacology of histone lysine methylation inhibitors

Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 27 · see citing works

Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors

Lanzi, C., Arrighetti, N., Pasquali, S., & Cassinelli, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115727 · Cited by 27 · see citing works

Amine Catalysis with Substrates Bearing N‐Heterocyclic Moieties Enabled by Control over the Enamine Pyramidalization Direction

Möhler, J. S., Schnitzer, T., & Wennemers, H. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002966 · Cited by 26 · see citing works

Reprogramming CBX8-PRC1 function with a positive allosteric modulator

Suh, J. L., Bsteh, D., Hart, B., Si, Y., Weaver, T., Pribitzer, C., Lau, R., Soni, S., Ogana, H. A. N., Rectenwald, J. M., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.10.003 · Cited by 26 · see citing works

An overview of the development of EED inhibitors to disable the PRC2 function

Liu, K., Zhu, K., & Zhang, H. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00274k · Cited by 26 · see citing works

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition

Zhang, K., Shen, Q., Fang, Y., Sun, Y.-M., Ding, J., & Chen, Y. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0248-2 · Cited by 25 · see citing works

Targeting Epigenetic protein–protein Interactions With small-molecule Inhibitors

Linhares, B. M., Grembecka, J. E., & Cierpicki, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0082 · Cited by 25 · see citing works

Chemical inhibitors targeting histone methylation readers

Huang, X., Chen, Y., Xiao, Q., Shang, X., & Liu, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108614 · Cited by 24 · see citing works

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins

(2024) · doi:10.1021/acs.jmedchem.4c02010 · Cited by 24 · see citing works

An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer

Dardis, G., Wang, J., Simon, J. M., Wang, G. G., & Baldwin, A. S. (2023) · iScience · doi:10.1016/j.isci.2023.107115 · Cited by 24 · see citing works

ALARM NMR for HTS Triage and Chemical Probe Validation

Dahlin, J. L., Cuellar, M. E., Singh, G., Nelson, K. M., Strasser, J. M., Rappe, T. M., Xia, Y., Veglia, G., & Walters, M. A. (2018) · Current Protocols in Chemical Biology · doi:10.1002/cpch.35 · Cited by 24 · see citing works

Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal

Turner, A. W., Dronamraju, R., Potjewyd, F., James, K. S., Winecoff, D., Kirchherr, J., Archin, N. M., Browne, E. P., Strahl, B. D., Margolis, D. M., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00514 · Cited by 24 · see citing works

Control of endothelial cell function and arteriogenesis by MEG3:EZH2 epigenetic regulation of integrin expression

Dunn-Davies, H., Dudnakova, T., Nogara, A. M., Rodor, J., Thomas, A. C., Parish, E., Gautier, P. E., Meynert, A. M., Ulitsky, I., Madeddu, P. R., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102173 · Cited by 23 · see citing works

Clinical significance and biological function of WD repeat domain 54 as an oncogene in colorectal cancer

Yuan, Y., Qi, G., Shen, H., Guo, A., Cao, F., Zhu, Y., Xiao, C., Chang, W., & Zheng, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31736 · Cited by 23 · see citing works

Polycomb group proteins in cancer: multifaceted functions and strategies for modulation

Wang, S. P., Ordonez‐Rubiano, S. C., Dhiman, A., Jiao, G., Strohmier, B. P., Krusemark, C. J., & Dykhuizen, E. C. (2021) · NAR Cancer · doi:10.1093/narcan/zcab039 · Cited by 23 · see citing works

Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics

Bao, Q., Kumar, A., V, Wu, D., & Zhou, J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103986 · Cited by 22 · see citing works

Targeting the EED–H3K27me3 Interaction Allosterically Inhibits PRC2

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2017-030 · Cited by 2 · see citing works

Binding Modes of Small‐Molecule Inhibitors to the EED Pocket of PRC2

Huang, D., Tian, S., Qi, Y., & Zhang, J. Z. H. (2019) · ChemPhysChem · doi:10.1002/cphc.201900903 · Cited by 14 · see citing works

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2304 · Cited by 316 · see citing works

Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED

Li, L., Zhang, H., Zhang, M., Zhao, M., Feng, L., Luo, X., Gao, Z., Huang, Y. R., Ardayfio, O., Zhang, J.-H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169855 · Cited by 53 · see citing works

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)

Yang, C., & Wang, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00287 · Cited by 12 · see citing works